Navigation Links
Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs

- Results Presented at Endocrine Society's 90th Annual Meeting -

SAN FRANCISCO and EMERYVILLE, Calif., June 16 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) today announced results on the role of estrogen regulatory elements important in developing drugs for breast cancer and osteoporosis. The data, which were presented at the Endocrine Society's 90th Annual Meeting, showed that the new regulatory elements are essential for the differentiation of the estrogenic pharmacological activity exerted by different compounds.

"Selective estrogen receptor modulators (SERMs) differ from estrogen in how they regulate gene transcription and result in different pharmacological profiles and clinical effects," said Dr. Dale Leitman, from the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco. "This study identified gene elements that are activated by SERMs but not by estrogens used in hormone therapy. The identification of these elements, coupled with the understanding of the differential regulation in various tissues, provides a new platform for the discovery of estrogenic drugs with SERM-like profiles."

The study was conducted by investigators at The Center for Reproductive Sciences in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco in collaboration with scientists at Bionovo.

"The discovery of these selective estrogen regulatory elements strengthens our SERM discovery engine," said Isaac Cohen, Bionovo's chairman and chief executive officer. "The advantage of the new array of specific regulatory elements is manifest in the pharmacological and toxicological insights gained. We can now acquire higher predictive value and greater specificity from a very complex biological system. I believe this puts Bionovo at the forefront of more rapidly developing future SERM products which are far more specific."

About Bionovo's SERM Platform

Bionovo is discovering and developing a new generation of novel selective estrogen modulators. The selectivity is based on receptor subtype regulation, agonist, antagonist effect, selective gene activation and repression and specific recruitment of co-regulatory proteins. Selective estrogen receptor modulators can be useful for many indications in women's health such as breast and uterine cancer, osteoporosis, menopausal symptoms, vaginal atrophy, endometriosis, uterine fibroids and other disorders. This platform provides Bionovo the molecular, pharmacological and toxicological insights needed for drugs of the future.

About Bionovo

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, which are markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE Bionovo Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
2. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
3. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
4. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
5. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
6. Video: New Research Discovers Independent Brain Networks Control Human Walking
7. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
8. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
9. XTENT Announces European Regulatory Update
10. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
11. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
Post Your Comments:
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
(Date:11/25/2015)...  ARKRAY USA , Inc., a ... demonstrating the accuracy of its blood glucose meter systems. ... Diabetes and Cardiovascular Disease in Los Angeles ... ® 01 meter and the Assure ® ... to accurately measure glucose levels in blood is essential ...
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan ... a franchise owner, Somu now offers travelers, value and care based Travel Services, ... cruise sales, as well as, cabin upgrades and special amenities such as, shore ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes ... titles work with any font, giving users limitless opportunities to stylize and create ...
(Date:11/25/2015)... ... , ... The holiday season is jam-packed with family dinners, ... attendees is of the utmost importance. Whether you are cooking at home for ... a try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... November 26, 2015 , ... ... European Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, ... (UNON) for the opening of the 5th African Network for Drugs and Diagnostics ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dental professionals ... in Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring ... year in Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), ...
Breaking Medicine News(10 mins):